BIVDA welcomes the fully agreed text of the UK–US pharmaceutical partnership, which delivers preferential terms for medical technology exports and sets out a pathway towards mutual recognition of medical device approvals.

These measures mark an important step in reducing barriers to trade and supporting faster access to innovative health technologies across both markets.

The agreement confirms that UK medical technology exports to the United States will face no additional tariffs for at least three years, giving valuable certainty to in vitro diagnostics (IVD) manufacturers and helping to unlock further investment in UK-based innovation and production.

Commitments to work towards mutual recognition of regulatory approvals have the potential to streamline processes, reduce duplication, and accelerate patient access to cutting-edge diagnostics.

BIVDA Chief Executive Helen Dent said: ‘Medical technology plays a vital role in improving patient outcomes and driving economic growth in the UK.

'We are therefore encouraged that this announcement reflects the Government’s recognition of that contribution and are optimistic that preferential terms and steps towards mutual recognition will help to support homegrown IVD innovation and ensure patients can benefit more quickly from the latest advances in diagnostics.’